Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2022-06-18 Major Shareholding Noti…
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document text contains detailed information about promoter holdings, encumbrance events, and share percentages related to a company. It references SEBI regulations concerning substantial acquisition of shares and takeovers (SAST Regulations). The content is focused on shareholding disclosures and changes in promoter share encumbrance. There is no indication of financial statements, management discussion, earnings data, or meeting materials. The document is a notification of changes in significant share ownership or encumbrance levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document length is short and does not contain a full report, so it is not an Annual Report or Interim Report. Therefore, the best classification is MRQ with high confidence.
2022-06-18 English
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to a specific regulation (Regulation 23(9) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015). It provides details of related party transactions for the half year ended March 31, 2022. The document is relatively short (1417 characters) and appears to be a regulatory compliance filing rather than a full financial report or detailed management discussion. It does not contain comprehensive financial statements or detailed analysis typical of interim or annual reports. It is also not an announcement of voting results, board changes, or other specific categories. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-06-07 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the issuance of duplicate share certificates due to lost original certificates. The content is a regulatory compliance announcement related to share certificates, not a financial report, management change, or voting result. The document length is short (1544 characters) and it serves as a notification to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-30 English
Newspaper Advertisements
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Medicamen Biotech Limited to stock exchanges (BSE and NSE) regarding the publication of audited financial results for the quarter and year ended March 31, 2022. It references compliance with SEBI regulations and includes extracts of standalone and consolidated audited financial results. The document contains actual financial data such as total income from operations and net profit for the period, indicating it is a financial report rather than just an announcement. The length of the document (15,000 characters) and the presence of detailed financial figures confirm it is not merely a publication announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR), as it covers quarterly and annual audited financial results with substantive financial data and analysis.
2022-05-26 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Medicamen Biotech Limited regarding the outcome of a Board Meeting held on 25.05.2022. It includes approval of audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2022, along with the statutory audit report, dividend recommendation, and appointments of auditors. The document contains actual financial data tables with income, expenses, profit, and tax details for the specified periods. It also references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes auditor opinions. The length of the document (15,000 characters) and the inclusion of detailed financial statements and audit reports indicate this is not merely an announcement but the actual financial results and audit report. Therefore, this filing is best classified as an Interim / Quarterly Report (IR) because it covers quarterly and annual audited financial results with substantive financial data and analysis, but it is not a full Annual Report (10-K). It also includes the audit report as part of the filing, which is typical in quarterly/year-end financial results announcements. Hence, the classification is IR with high confidence.
2022-05-25 English
Board Meeting — Dividend/Financial results
Regulatory Filings Classification · 95% confidence The document is an intimation letter from Medicamen Biotech Limited to stock exchanges regarding a scheduled Board of Directors meeting to consider and approve audited financial results for the quarter/year ended March 31, 2022, dividend recommendation, and auditor appointments. It is a notification of an upcoming board meeting and related agenda items, not the actual financial results or reports themselves. The document is short (2811 characters) and serves as an announcement under SEBI Listing Obligations and Disclosure Requirements Regulations. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain actual financial statements or detailed report content.
2022-05-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.